Astrana Q2 revenue rises 35% but misses analyst expectations

Overview

• Astrana Q2 2025 revenue rises 35% yr/yr but misses analyst expectations, per LSEG data

• Adjusted EBITDA for Q2 at higher end of co's guidance

• Company completed acquisition of Prospect Health, enhancing growth prospects

Outlook

• Astrana sees Q3 revenue between $925 mln and $965 mln

• Company expects full-year revenue between $3.1 bln and $3.3 bln

• Astrana anticipates Q3 adjusted EBITDA of $65 mln to $70 mln

• Company reiterates full-year guidance including Prospect Health acquisition

Result Drivers

• REVENUE GROWTH - Total revenue increased by 35% year-over-year, driven by effective management of medical cost trends

• TECHNOLOGY PLATFORM - Company's technology-enabled model contributed to strong results, providing real-time visibility into patient health

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy"

• Wall Street's median 12-month price target for Astrana Health Inc is $46.00, about 52.6% above its August 6 closing price of $21.81

• The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release: ID:nPn2rdyrwa